Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT

OBJECTIVES: The IMPACT trial has compared the benefit in the reduction of moderate/severe exacerbations of single inhaler triple therapy (SITT) with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus dual therapy with FF/VI (ICS/LABA) and UMEC/VI (LAMA/LABA) in the treatment of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Marín, José M., Mateos, Luis, Roldán, Juan, Echave-Sustaeta, José M., Pascual-Guardia, Sergi, Pardo, Maria V., Velasco, Beatriz, Jones, C. Elaine, Kilbride, Sally, Lipson, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607727/
https://www.ncbi.nlm.nih.gov/pubmed/33121372
http://dx.doi.org/10.1177/1753466620963021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607727/
https://www.ncbi.nlm.nih.gov/pubmed/33121372
http://dx.doi.org/10.1177/1753466620963021

Ejemplares similares